Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-324,173
Closed -$4.13M 76
2022
Q4
$4.13M Sell
324,173
-330,689
-50% -$2.98M 1.16% 27
2022
Q3
$3.79M Sell
654,862
-111,912
-15% -$492K 1.02% 32
2022
Q2
$2.47M Buy
766,774
+442,721
+137% +$1.34M 0.67% 39
2022
Q1
$1.22M Buy
324,053
+179,400
+124% +$1.16M 0.32% 66
2021
Q4
$1.89M Buy
144,653
+18,001
+14% +$285K 0.48% 45
2021
Q3
$2.48M Buy
126,652
+10,200
+9% +$186K 0.66% 39
2021
Q2
$2.18M Buy
116,452
+10,974
+10% +$245K 0.46% 48
2021
Q1
$2.5M Hold
105,478
0.59% 41
2020
Q4
$2.57M Sell
105,478
-5,000
-5% -$128K 0.76% 32
2020
Q3
$2.83M Buy
110,478
+90,000
+439% +$2.85M 0.92% 28
2020
Q2
$408K Buy
+20,478
New +$498K 0.12% 78

Other funds holding ETNB

DAFNA Capital Management's ETNB Position: Q1 2023 in Review

DAFNA Capital Management sold out of 89bio (ETNB) in Q1 2023, closing a stake of 324,173 shares — an estimated $4.13M sold.

DAFNA Capital Management first reported a position in ETNB in Q2 2020 and held it in 11 quarters. The position peaked at $4.13M in Q4 2022. 145 funds tracked by Wall St. Rank hold ETNB as of Q1 2023.

  • DAFNA Capital Management reported no remaining 89bio position as of Q1 2023 after selling out during the quarter.
  • DAFNA Capital Management sold 324,173 89bio shares in Q1 2023, an estimated $4.13M.
  • DAFNA Capital Management first reported a position in 89bio in Q2 2020 and held it in 11 quarters.
  • DAFNA Capital Management's 89bio position peaked at $4.13M in Q4 2022.
  • 145 funds tracked by Wall St. Rank held 89bio as of Q1 2023.

Based on DAFNA Capital Management's 13F filing for Q1 2023, filed 15 May 2023.